MSMostafa Abd Alfattah Shamkh

Mostafa Abd Alfattah Shamkh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mostafa Abd Alfattah Shamkh has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Ahmed Fouad Sherief

    Inflammatory bowel disease unit, Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    1 shared publication
  • Ahmed Sherief

    Department of Tropical Medicine, Faculty of Medicine, Ain Shams University Abbasia square, Cairo, Egypt

    1 shared publication
  • Amira Mahmoud Al Balakosy

    Ain Shams University, Cairo, Egypt

    1 shared publication
  • Azza Hassan

    Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Abbasia Square, Cairo, Egypt

    1 shared publication
  • Ethar Badran

    Department of Tropical Medicine, Faculty of Medicine, Ain Shams University Abbasia square, Cairo, Egypt

    1 shared publication
  • Hany Dabbous

    Department of Tropical Medicine, Faculty of Medicine, Ain Shams University Abbasia square, Cairo, Egypt

    1 shared publication

Latest Publications

  • Open Access

    A decade of inflammatory bowel disease: a single center experience in Egypt

    by Mostafa Abd Alfattah Shamkh, Mohamed Amin Sakr, Waleed Hamed Abd Alaty, Shimaa Youssef Kamel, Mohamed Mahmoud Eltabbakh, Ahmed Fouad Sherief, Heba Rashad, Safaa Askar

    Background: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract and includes ulcerative colitis and Crohn’s disease. Inflammatory bowel disease has always seemed to be rare in the Middle East and Northern Africa. In this study, we explored the clinical characteristics of inflammatory bowel disease patients in our center. Methods: This retrospective study was conducted on patients with an established diagnosis of inflammatory bowel disease over 10 years from September 2009 to September 2019 who were referred to our inflammatory bowel disease center. Clinical information was obtained from medical records and patient interviews. We included all patients in whom the diagnosis of ulcerative colitis or Crohn’s disease was confirmed by clinical, laboratory, endoscopic, and histological examination over a 10-year period from 2009 to 2019. Results: Our study had one hundred and sixty-nine inflammatory bowel disease patients; one hundred and thirty-six ulcerative colitis patients and the remaining thirty-three patients had Crohn’s disease. The main presenting symptom was bloody diarrhea (78 patients) representing 46.2% of the patients in our study. The majority of ulcerative colitis patients (55.9%) had moderate disease (Truelove & Witts score), while the majority of Crohn’s disease patients (66.7%) had moderate to severe disease (Crohn’s Disease Activity Index). Conclusions: The prevalence of inflammatory bowel disease is still low in Egypt despite the rising curve of newly diagnosed cases.


  • Measles IgG Antibodies: Is There a Protective Role in COVID 19 Pandemic?‎ ‎

    by Amira Al Balakosy, Mostafa Alfishawy, Omnia Elnabawy, Azza Hassan, Mostafa Shamkh, Mahmoud Mahmoud, Ethar Badran, Hany Dabbous, Osama Ahmed, Rana Taha, et al.

    Background and study aim: Epidemiological data reported lower death rates of COVID-19 cases in countries with higher & ‎recent coverage by measles containing vaccines. In this study we aim to identify measles IgG titer ‎in COVID-19 patients & correlate it with disease severity‎‎‎‎. Patients and Method: ‎This is a Cross-sectional study where 78 patients admitted to Ain Shams University Quarantine ‎hospitals with positive PCR for SARS-CoV-2 were enrolled. All patients underwent ‎quantification of serum measles IgG titer. Then classified according to the COVID-19 severity ‎into mild, moderate and severe‎‎.‎ Results: Measles IgG was positive in 53 patients (68%) with median of 1600 (IQR 1000-or3100), borderline ‎in 18 patients (23%) with median 250 (IQR 200-250) and negative in seven patients (9%) with ‎median 100 (IQR 80-120). Patients with positive measles IgG were significantly older (56±16 ‎years) than those with negative measles IgG ( 48±15 years) (P=0.03).No significant difference ‎was found in measles IgG titer between mild , moderate and severe COVID19 cases. Intensity of ‎pulmonary involvement by CT chest was not correlated with measles IgG titer. The median of ‎measles IgG titer of the ICU admitted patients and those who were not, was 1150 (IQR=600-3500) ‎and 1050 (IQR=200-1800) respectively (p=0.46). No difference in measles IgG titer between ‎patients who recovered or died‎‎‎. Conclusion: Severity of COVID-19 disease and its outcome seem to be unaffected by measles IgG titer‎‎‎‎‎.